MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
CytomX Therapeutics, Inc. (NASDAQ: CTMX)*
Organization & Developments: CytomX
Parents
CytomX Therapeutics, Inc. (NASDAQ: CTMX)*
Children
*Biopharmaceutical company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer.
*Cytomx is aiming its monoclonal antibodies at oncology, inflammation, and other areas.
2017: CytomX Therapeutics: A Possible ASCO Runner For Next Year - CytomX Therapeutics (NASDAQ:CTMX)
2022: CytomX halts lead program and will seek a partner as breast cancer drug disappoints
2022: Reeling from PhII flop, CytomX lays off 40% as execs go back to drawing board, seek new deals
2023: Moderna Leans into Oncology with CytomX Deal Worth up to $1.2B
2025:CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish?
Jumps
*Key People: CytomX
Finance & Acquisitions: CytomX